STOCK TITAN

INTEGRA LIFESCIENCES HOLDINGS (IART) SEC Filings, Jul 2-9, 2025

IART NASDAQ

Integra LifeSciences Holdings Corporation filings document regulatory disclosures for a Nasdaq-listed medical technology issuer with common stock registered under Section 12(b). Forms 8-K cover operating results and financial condition, including GAAP-to-non-GAAP reconciliations for organic revenue, adjusted EBITDA, adjusted earnings per share, net debt and free cash flow, as well as guidance-related disclosures.

Proxy and material-event filings address board elections, shareholder voting, executive compensation and equity incentive plan amendments. Other filings describe leadership appointments, employment and severance arrangements, and financing matters such as the company’s accounts receivable securitization facility used for liquidity and ongoing business funding.

Schedule 13G/A
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
other
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
insider
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
insider
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
insider

FAQ

How many INTEGRA LIFESCIENCES HOLDINGS (IART) SEC filings are available on StockTitan?

StockTitan tracks 64 SEC filings for INTEGRA LIFESCIENCES HOLDINGS (IART), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for INTEGRA LIFESCIENCES HOLDINGS (IART)?

The most recent SEC filing for INTEGRA LIFESCIENCES HOLDINGS (IART) was filed on November 10, 2026.